NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9478	Companies
185480	Keywords
117823	Articles
99321	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/22/2025 at 12:30, 6 months 14 days ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. comments on the new COVID Vaccine Booster Shots policy adopted by the US FDA with focus on specific high-risk groups. Dr. Anil Diwan emphasizes evidence-based decision making for vaccine boosters

NanoViricides Inc. COVID Vaccine Booster Shots US FDA Policy Vaccine Effectiveness Dr. Anil Diwan
BRIEF

published on 05/16/2025 at 12:35, 6 months 20 days ago

NanoViricides fait progresser l'antiviral NV-387 dans les essais de phase II

Essai De Phase II Mise À Jour Financière Antiviral À Large Spectre Traitement MPox Épidémie De Rougeole
BRIEF

published on 05/16/2025 at 12:35, 6 months 20 days ago

NanoViricides Advances Antiviral NV-387 in Phase II Trials

Phase II Trial Financial Update Broad-spectrum Antiviral MPOX Treatment Measles Outbreak
PRESS RELEASE

published on 05/16/2025 at 12:30, 6 months 20 days ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 6 months 22 days ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé
BRIEF

published on 05/14/2025 at 12:35, 6 months 22 days ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
PRESS RELEASE

published on 05/14/2025 at 12:30, 6 months 22 days ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 6 months 28 days ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
BRIEF

published on 05/08/2025 at 12:35, 6 months 28 days ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 6 months 28 days ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease

Accesswire

Published on 12/05/2025 at 15:00, 27 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 27 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 27 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 12 hours 57 minutes ago

Klondike Gold Announces AGM Results

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:05, 21 minutes ago

Seegene Establishes French Subsidiary to Expand European Footprint
Published on 12/05/2025 at 14:22, 1 hour 4 minutes ago

EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 1 hour 10 minutes ago

Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 1 hour 16 minutes ago

The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 41 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings

Les Echos

Published on 12/05/2025 at 15:10, 16 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 16 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 28 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 42 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 42 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE